ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,229Medicare Part D Prescriptions Filled, Including Refills

Rank: 240 out of 1185

$448K Total Retail Price of All Prescriptions

Rank: 328 out of 1185

442 Patients Receiving at Least One Drug in Part D
67%Patients 65 Years and Older
70% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in South Carolina
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 442 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

17% of this provider’s 442 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

2% of this provider’s 5,714 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

26% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$49 was the average price of a prescription from this provider, compared to $57 among peers.

Prescriptions per Patient

21 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in South Carolina
OMEPRAZOLE 388 244 1 6
HYDROCODONE-ACETAMINOPHEN 366 248 S3 2 2
AMLODIPINE BESYLATE 356 222 3 1
SIMVASTATIN 350 183 4 5
LISINOPRIL 279 135 5 4
LEVOTHYROXINE SODIUM 277 170 6 3
PRAVASTATIN SODIUM 262 201 7 7
METFORMIN HCL 255 159 8 9
FUROSEMIDE 155 120 9 8
HYDROCHLOROTHIAZIDE 132 47 10 12
SERTRALINE HCL 119 52 11 25
METOPROLOL TARTRATE 118 62 12 10
AMLODIPINE BESYLATE-BENAZEPRIL 113 88 13 42
ALENDRONATE SODIUM 109 76 14 40
ALLOPURINOL 104 83 15 30
ATORVASTATIN CALCIUM 99 75 16 11
FAMOTIDINE 98 31 17 69
MELOXICAM 98 67 17 27
LISINOPRIL-HYDROCHLOROTHIAZIDE 87 73 19 14
ZOLPIDEM TARTRATE 84 46 20 15
CITALOPRAM HBR 84 67 20 22
POLYETHYLENE GLYCOL 3350 82 24 22 60
DONEPEZIL HCL 82 69 22 32
SINGULAIR 82 68 22 106
NEXIUM 79 50 25 19
BENAZEPRIL HCL 77 53 26 41
GLIMEPIRIDE 75 46 27 49
FLUTICASONE PROPIONATE 73 48 28 29
TRAMADOL HCL 72 47 29 16
ACTOS 71 22 30 86
DIOVAN 71 42 30 37
PROAIR HFA 70 50 32 50
GABAPENTIN 67 30 33 13
METOPROLOL SUCCINATE 67 53 33 20
RANITIDINE HCL 66 12 35 17
ZETIA 62 50 36 78
FENOFIBRATE 62 31 36 55
TRIAMTERENE-HCTZ 59 28 38 71
WARFARIN SODIUM 59 54 38 21
POTASSIUM CHLORIDE 57 50 40 18
VENTOLIN HFA 57 45 40 83
CRESTOR 53 42 42 23
LANTUS 53 44 42 66
DOXAZOSIN MESYLATE 52 28 44 84
TRICOR 52 46 44 125
GLIPIZIDE 51 44 46 56
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 11, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.